Skip to main content

Telogen Effluvium

1
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Biolab Pharma
Biolab PharmaBrazil - São Paulo
1 program
1
BL 3000Phase 31 trial
Active Trials
NCT04880889Unknown326Est. Jul 2023
Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
Hair follicles samplingN/A1 trial
RV3466F lotionN/A1 trial
Active Trials
NCT04237402Completed20Est. Dec 2019
NCT04652232Completed100Est. Jun 2017
Lacer
LacerSpain - Barcelona
1 program
anti-hair loss shampooN/A1 trial
Active Trials
NCT07433933Completed40Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Biolab PharmaBL 3000
Laceranti-hair loss shampoo
Pierre FabreHair follicles sampling
Pierre FabreRV3466F lotion

Clinical Trials (4)

Total enrollment: 486 patients across 4 trials

NCT04880889Biolab PharmaBL 3000

BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

Start: Jan 2023Est. completion: Jul 2023326 patients
Phase 3Unknown
NCT07433933Laceranti-hair loss shampoo

Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss.

Start: May 2025Est. completion: Oct 202540 patients
N/ACompleted
NCT04237402Pierre FabreHair follicles sampling

Demonstration of the Presence of a Carbonyl Stress in the Hair Follicles of Postpartum Women

Start: Jun 2018Est. completion: Dec 201920 patients
N/ACompleted
NCT04652232Pierre FabreRV3466F lotion

Efficacy Study of Cosmetic Product Against Telogen Effluvium on Women

Start: Dec 2016Est. completion: Jun 2017100 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.